Literature DB >> 33632047

An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.

Hamed Hajipour1, Laya Farzadi2, Zeinab Latifi3, Neda Keyhanvar4, Nazli Navali2, Amir Fattahi1,5, Mohammad Nouri1, Ralf Dittrich5.   

Abstract

Administration of platelet-rich plasma (PRP) is one of the well-recommended strategies for the treatment of endometrium- and ovary-associated infertility. Due to the autologous source of PRP, minimal risks for disease transmission and immunogenic and allergic responses are expected in this method. Despite the extensive use of PRP in medicine, its precise mechanism of action in endometrial and ovarian tissues is still unknown. Nevertheless, the induction of cell proliferation, chemotaxis, regeneration, extracellular matrix synthesis, remodeling, angiogenesis, and epithelialization are the main pathways for PRP to affect female reproductive organs. Given the promising results of previous studies, it is necessary to standardize PRP preparation protocols for different therapeutic purposes and also clearly determine appropriate inclusion and exclusion criteria for recruiting patients. In the current review, we presented a summary of studies on PRP therapy for endometrium- and ovary-associated infertility with a focus on the possible mechanisms by which PRP enhances endometrial receptivity and regenerates ovarian function.Abbreviations: PRP: platelet-rich plasma; ART: assisted reproductive technology; POF: premature ovarian failure; TGF: transforming growth factors; PDGF: platelet-derived growth factors; IGF-I: insulin-like growth factor-1; HGF: hepatocyte growth factor; EGF: epidermal growth factor; FGF: fibroblast growth factor; VEGF: vascular endothelial growth factor; ADP: adenosine diphosphate, ATP: adenosine triphosphate; PDGF: platelet-derived growth factor; COX2: cyclooxygenase-2; TP53: tumor protein 53; ER-α: estrogen receptors alpha; ER-β: estrogen receptors beta; PR: progesterone receptor; RIF: recurrent implantation failure; G-CSF: granulocyte colony-stimulating factor; iNOS: inducible nitric oxide synthase; NF-kβ: nuclear factor kappa beta; MMPs: matrix metalloproteinases; Col1a1: collagen type I alpha 1; IL: interleukin; FSH: follicle-stimulating hormone; AMH: anti-Mullerian hormone; GDF-9: growth differentiation factor 9.

Entities:  

Keywords:  Platelet-rich plasma‎; endometrium; implantation; ovary

Mesh:

Substances:

Year:  2021        PMID: 33632047     DOI: 10.1080/19396368.2020.1862357

Source DB:  PubMed          Journal:  Syst Biol Reprod Med        ISSN: 1939-6368            Impact factor:   3.061


  5 in total

1.  Growth factors, gene activation, and cell recruitment: From intraovarian condensed platelet cytokines to de novo oocyte development.

Authors:  E Scott Sills; Samuel H Wood
Journal:  J Clin Transl Res       Date:  2022-01-25

2.  Potential of Plasma Rich in Growth Factors (PRGF-Endoret) to Enhance the Efficacy of Assisted Reproductive Techniques in Refractory Cases.

Authors:  Jon Ander Agirregoikoa; Jose Luis de Pablo; Maria de la Fuente; Eduardo Anitua
Journal:  Cureus       Date:  2022-07-06

Review 3.  Platelet-rich plasma use in meniscus repair treatment: a systematic review and meta-analysis of clinical studies.

Authors:  Ziquan Li; Xisheng Weng
Journal:  J Orthop Surg Res       Date:  2022-10-08       Impact factor: 2.677

Review 4.  Platelet-Rich Plasma: A Promising Regenerative Therapy in Gynecological Disorders.

Authors:  Jerin Varghese; Neema Acharya
Journal:  Cureus       Date:  2022-09-10

5.  Qilin Pill Exerts Therapeutic Effect on Resection-Induced Premature Ovarian Insufficiency Rats by Inhibiting the MAPK and PI3K-AKT Signaling Pathways.

Authors:  Debao Li; Yuling Jia; Yiwen Hou; Dingshi Chen; Chiyang Zheng; Lifen Chen; Li Zhou; Zuyue Sun
Journal:  Drug Des Devel Ther       Date:  2021-07-30       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.